VOSO, MARIA TERESA

VOSO, MARIA TERESA  

Dipartimento di Biomedicina e prevenzione  

Mostra records
Risultati 1 - 20 di 264 (tempo di esecuzione: 0.029 secondi).
Data di pubblicazione Titolo Autore(i) Tipo File
1-gen-2011 5-azacytidine in chronic myelomonocytic leukemia: case report and review of literature Greco, M; Criscuolo, M; Fianchi, L; Fabiani, E; Pagano, L; Voso, Mt Articolo su rivista
1-gen-2005 [Myeloproliferative disorders due to the use of gasoline as a solvent: report of three cases] Bernardini, P; Giannandrea, F; Voso, Mt; Sica, S Articolo su rivista
1-gen-2017 A Population-Based Study on Myelodysplastic Syndromes in the Lazio Region (Italy), Medical Miscoding and 11-Year Mortality Follow-Up: the Gruppo Romano-Laziale Mielodisplasie Experience of Retrospective Multicentric Registry Mayer, F; Faglioni, L; Agabiti, N; Fenu, S; Buccisano, F; Latagliata, R; Ricci, R; Spiriti, M; Tatarelli, C; Breccia, M; Cimino, G; Fianchi, L; Criscuolo, M; Gumenyuk, S; Mancini, S; Maurillo, L; Nobile, C; Niscola, P; Piccioni, A; Tafuri, A; Trapè, G; Andriani, A; DE FABRITIIS, P; Voso, Mt; Davoli, M; Zini, G Articolo su rivista
1-gen-2022 A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML Zeidan, Am; Boss, Iw; Beach, Cl; Copeland, Wb; Thompson, Eg; Fox, Ba; Hasle, Ve; Hellmann, A; Taussig, D; Tormo, M; Voso, Mt; Cavenagh, J; O'Connor, T; Previtali, A; Rose, S; Silverman, Lr Articolo su rivista
1-gen-2022 A randomized phase 2 trial of azacitidine ± durvalumab as first-line therapy for higher-risk myelodysplastic syndromes Zeidan, Am; Boss, Iw; Beach, Cl; Copeland, Wb; Thompson, Eg; Fox, Ba; Hasle, Ve; Ogasawara, K; Cavenagh, J; Silverman, Lr; Voso, Mt; Hellmann, A; Tormo, M; O'Connor, T; Previtali, A; Rose, S; Garcia-Manero, G Articolo su rivista
1-gen-2021 A Relapsing Meningeal Acute Myeloid Leukaemia FLT3-ITD+ Responding to Gilteritinib Perrone, S; Ortu La Barbera, E; Viola, F; Cipollone, E; Scerpa, Mc; Siniscalchi, R; Ottone, T; Voso, Mt; Cimino, G Articolo su rivista
15-gen-2004 Aberrant methylation of DAP-kinase in therapy-related acute myeloid leukemia and myelodysplastic syndromes Voso, Mt; Scardocci, A; Guidi, F; Zini, G; Di Mario, A; Pagano, L; Hohaus, S; Leone, G Articolo su rivista
16-mar-2020 Absence of FGFR3-TACC3 rearrangement in hematological malignancies with numerical chromosomal alteration Banella, C; Ginevrino, M; Catalano, G; Fabiani, E; Falconi, G; Divona, M; Curzi, P; Panetta, P; Voso, Mt; Noguera, Ni Articolo su rivista
1-ago-2015 Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes Caocci, G; Voso, Mt; Angelucci, E; Stauder, R; Cottone, F; Abel, G; Nguyen, K; Platzbecker, U; Beyne Rauzy, O; Gaidano, G; Invernizzi, R; Molica, S; Criscuolo, M; Breccia, M; Lübbert, M; Sanpaolo, G; Buccisano, F; Ricco, A; Palumbo, G; Niscola, P; Zhang, H; Fenu, S; La Nasa, G; Mandelli, F; Efficace, F Articolo su rivista
1-ago-2003 Acute myeloid leukemia in elderly patients aged over 75 years: experience of a single centre Di Febo, A; Mele, L; Fianchi, L; Scardocci, A; Voso, Mt; Falcucci, P; Trapè, G; Leone, G; Pagano, L Articolo su rivista
1-gen-2021 Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols Rosati, S; Gurnari, C; Breccia, M; Carmosino, I; Scalzulli, E; Montefusco, E; Perrone, S; Annibali, O; Martini, V; Trapè, G; Colafigli, G; Trawinska, M; Minotti, C; Cimino, G; Tafuri, A; Avvisati, G; Martelli, M; Voso, Mt; Latagliata, R Articolo su rivista
1-ott-2020 Acute Promyelocytic Leukemia After Radium-223 Exposure for Prostate Cancer in a Chemotherapy-Naïve Patient Perrone, S; Ortu La Barbera, E; Ottone, T; Capriata, M; Passucci, M; Filippi, L; Bagni, O; Voso, Mt; Cimino, G Articolo su rivista
11-gen-2021 Acute Promyelocytic Leukemia in Children: A Model of Precision Medicine and Chemotherapy-Free Therapy Gurnari, C; Voso, Mt; Girardi, K; Mastronuzzi, A; Strocchio, L Articolo su rivista
1-ott-2019 Acute promyelocytic Leukemia: Update on the mechanisms of leukemogenesis, resistance and on innovative treatment strategies Noguera, Ni; Catalano, G; Banella, C; Divona, M; Faraoni, I; Ottone, T; Arcese, W; Voso, Mt Articolo su rivista
1-gen-1999 Adjuvant high-dose therapy with peripheral blood stem cell support for patients with high-risk breast cancer Hohaus, S; Martin, S; Schneeweiss, A; Voso, Mt; Schlenk, R; Wallwiener, D; Bastert, G; Haas, R Articolo su rivista
1-gen-2021 AMELIORATE: early intensification in FLT3-mutated acute myeloid leukemia based on peripheral blast clearance - MYNERVA-GIMEMA AML1919 trial Mannelli, F; Gianfaldoni, G; Guglielmelli, P; Buccisano, F; Caporale, R; Chiarini, M; Rossi, G; Venditti, A; Fazi, P; Crea, E; Piciocchi, A; Voso, Mt; Vignetti, M; Amadori, S; Vannucchi, Am Articolo su rivista
1-gen-2022 AML: making residual disease more measurable Voso, Mt; Buccisano, F Articolo su rivista
1-gen-2015 An abnormal secretion of soluble mediators contributes to the hematopoietic-niche dysfunction in low-risk myelodysplastic syndrome Martini, M; Capodimonti, S; Iachininoto, M; Cocomazzi, A; Nuzzolo, E; Voso, Mt; Teofili, L; Larocca, L Articolo su rivista
1-mag-2015 An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms Breccia, M; Voso, Mt; Aloe Spiriti, M; Fenu, S; Maurillo, L; Buccisano, F; Tafuri, A; Alimena, G Articolo su rivista
1-gen-2022 An Polycythemia Vera Evolve from Acute Myeloid Leukemia? Report of a Case Showing a Simultaneous Minor JAK2 V617F Mutated Clone Borsellino, B; Savi, A; Pascale, M; Meddi, E; Del Principe, M; Cristiano, A; Ottone, T; Rapanotti, M; Divona, M; Travaglini, S; Attardi, E; Palmieri, R; Buzzatti, E; Buccisano, F; Voso, M Articolo su rivista